Mesoblast MESO
NASDAQ MESO
$17.32 +0.18 (+1.05%)
At close: Sep 4, 2026 · 4:00 PM EDT

Mesoblast (MESO) Income from Continuing Operations (2014 - 2023)

Mesoblast (MESO) posted Income from Continuing Operations of 21919000.0 for Q2 2023, down 17.84% sequentially from 18600000.0 in Q1 2023, and down 2.16% YoY from 22403513.17 in Q2 2022.

Analysis

Mesoblast (MESO) Income from Continuing Operations (2014 - 2023) Analysis & Trends

Mesoblast has reported Income from Continuing Operations for 10 years, with the latest figure at 21919000.0 in Q2 2023.

  • Quarterly Income from Continuing Operations fell 2.16% year-over-year to 21919000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was 81889000.0 (up 10.35% YoY) and the FY2025 annual result came in at 102142000.0, down 16.13% from the prior year.
  • Income from Continuing Operations eased to 21919000.0 in Q2 2023 per MESO's latest filing, from 18600000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 5484000.0 in Q3 2019 and troughed at 32610000.0 in Q2 2020.
  • A 5-year average of 21982444.44 and a median of 22352500.0 in 2021 frame the typical range for Income from Continuing Operations.
  • The sharpest annual moves came in 2019 and 2020: Income from Continuing Operations jumped 71.87% in 2019, then tumbled 347.56% in 2020.
  • Over 5 years, Income from Continuing Operations stood at 24584000.0 in 2019, then fell by 4.51% to 25692000.0 in 2020, then dropped by 0.98% to 25945000.0 in 2021, then advanced by 5.62% to 24486000.0 in 2022, then increased by 10.48% to 21919000.0 in 2023.
  • According to Business Quant data, Income from Continuing Operations over the past three periods registered 21919000.0, 18600000.0, and 24486000.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 601.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -644.37 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 81.49 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -13.27 Mn
10 Mesoblast 2.24 Bn 2.14 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 -21.58 Mn
Mar 31, 2023 -18.69 Mn
Dec 31, 2022 -24.63 Mn
Sep 30, 2022 -16.99 Mn
Jun 30, 2022 162.09 Mn
Mar 31, 2022 -21.39 Mn
Dec 31, 2021 -26.11 Mn
Sep 30, 2021 -22.77 Mn
Jun 30, 2021 178.71 Mn
Mar 31, 2021 -26.71 Mn
Dec 31, 2020 -25.54 Mn
Sep 30, 2020 -26.00 Mn
Mar 31, 2020 -57.65 Mn
Dec 31, 2019 -38.47 Mn
Sep 30, 2019 -9.35 Mn
Jun 30, 2019 -27.08 Mn
Mar 31, 2019 -29.38 Mn
Dec 31, 2018 -30.33 Mn
Sep 30, 2018 -20.92 Mn
Jun 30, 2018 -22.88 Mn